We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.10 | -0.47% | 21.30 | 1,317,400 | 16:35:26 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 21.20 | 21.50 | 21.35 | 21.35 | 21.35 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | EUR 56.04M | EUR 16.12M | EUR 0.0237 | 9.01 | 145.6M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:26 | O | 760,770 | 21.474 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/11/2024 | 07:00 | UK RNS | hVIVO PLC Holding(s) in Company |
| 06/11/2024 | 07:00 | UK RNS | hVIVO PLC Holding(s) in Company |
| 05/11/2024 | 07:00 | UK RNS | hVIVO PLC Presentation at Jefferies London Healthcare Conf |
| 11/10/2024 | 06:00 | UK RNS | hVIVO PLC Long Term Incentive Plan/ PDMR Notification |
| 07/10/2024 | 06:00 | UK RNS | hVIVO PLC Positive results from RSV human challenge trial |
| 30/9/2024 | 06:00 | UK RNS | hVIVO PLC Launch of full suite of hLAB standalone services |
| 24/9/2024 | 06:00 | UK RNS | hVIVO PLC Holding(s) in Company |
| 17/9/2024 | 06:00 | UK RNS | hVIVO PLC Holding(s) in Company |
| 13/9/2024 | 06:00 | UK RNS | hVIVO PLC Holding(s) in Company |
| 10/9/2024 | 14:53 | ALNC |  hVIVO hails "record" half-year revenue, as profit soars 70% higher |
Hvivo (HVO) Share Charts1 Year Hvivo Chart |
|
1 Month Hvivo Chart |
Intraday Hvivo Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 03/12/2024 | 14:57 | hVIVO plc | 8,848 |
| 25/11/2024 | 13:34 | Profit warning now likely | 6 |
| 15/8/2024 | 16:32 | HVIVO (litter free) | 56 |
| 10/4/2024 | 06:01 | HVIVO (litrer free) | 2 |
| 26/10/2022 | 07:49 | hVIVO plc | 2,750 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 17:15:00 | 21.47 | 760,770 | 163,367.75 | O |
| 16:35:26 | 21.30 | 137,089 | 29,199.96 | UT |
| 15:50:54 | 21.25 | 5,000 | 1,062.50 | O |
| 15:29:54 | 21.35 | 495 | 105.68 | O |
| 15:29:24 | 21.35 | 495 | 105.68 | O |
| Top Posts |
|---|
Posted at 03/12/2024 08:20 by Hvivo Daily Update Hvivo Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HVO. The last closing price for Hvivo was 21.40p.Hvivo currently has 680,371,877 shares in issue. The market capitalisation of Hvivo is £145,259,396. Hvivo has a price to earnings ratio (PE ratio) of 9.01. This morning HVO shares opened at 21.35p |
Posted at 26/11/2024 13:46 by malcolmz1 Nothing to worry about other than the share price has been decimated and long term holders have seen their paper profits disappear just before Christmas. share price at same level as summer 2020. |
Posted at 26/11/2024 13:34 by pogue Email from the companyThanks for your email. The company is of course aware of the recent share price weakness but is concentrated on factors within its control. hVIVO reiterated its guidance in September for £62 million in revenue with full year EBITDA margins anticipated to be at the upper end of market expectations for 2024, and there has been no change to this. If there are any material changes to expectations, the company would be required to issue an RNS to update the market. It is not in the company’s interest to make a habit of commenting on movements in share price or the decision-making of individual investors, for which there is a large number of contributing influences. It is in the nature of hVIVO’s business model for there to be gaps between contract announcements. Decisions on whether clients proceed with a challenge trial are complex and affected by a number of different factors outside of hVIVO’s control. The Company did announce in its interim results that it had a pipeline of live short to medium term opportunities of c. £40million. The company remains confident in the long-term growth of the business and human challenge trial market, and its medium term growth target of growing Group revenue to £100 million by 20 |
Posted at 25/11/2024 11:45 by sikhthetech Yump"The risks of no contract news and institutions stopping buying was talked about before your time back in July/August." Wrong. The red flag was when CF dumped majority of his holding in Feb, whilst the company was being talked up. Together with the huge >7m options awarded to the CEO, these were huge red flags. My assertions and warnings have been consistent and foresight. My assertions/opinions have been: These are being talked up so they can sell. The chairman DID sell majority of his holding in Feb 2024, whilst the company was being talked up. I said that's a red flag. Rampers ridiculed me by saying he still retains a sizeable holding!!! The chairman then dumped his entire holding in July 2024, just 4 working days after the TU. I said that was a huge red flag. The Chairman sells 28p/29p has set a ceiling to the share price I believe the chairman knows more about the company than any PI or II. The CEO has huge >7m options, which were back dated a year and start to exercise from Feb 2025. The shares will continue to be talked up. As far as I'm aware, Feb 2025 is still 3 months away!! Do you disagree? Awarding such huge options to 1 exec is a red flag. Cash. I believe clients largely paid for the new facility because HVO need to save cash for H2. Likewise the reasons why they don't pay normal dividends. Buying stops. The share price will drop when the II stops buying, as selling will continue. If there's huge demand then there's nothing stopping others entering the market. £200m mcap for a company with revenues of only £50m-£60m is too high. Questionable business model. Lack of 2025 revenue guidance is a red flag. These are being pumped/dumped by the same blnx gang, using multiple ids. |
Posted at 21/11/2024 16:28 by sikhthetech Chica,I was posting facts and opinions based on facts. They do have a questionable business model. The same questions still exist, when they were around 10p. Look at the share price reaction, the share price started to rise after the CEO received his >7m options and not when he was appointed CEO. The huge options were back dated, another red flag. There were lots of bullish notes, company talked up, so obviously some will buy in, hence the price rise. What happened to DiM? Why the new facility largely paid for by clients when they supposedly got £37m in the bank? Why lack of normal dividend? The red flag was the company being talked up soon after the CEO was awarded his huge options. That was more than a year ago. Since then: Revenue growth rate DID slow. CF DID dump his entire holding. There ARE a lack of contracts What agenda? You referring to 1gw and his mates. A poster who has a long history of ramping and those shares eventually crashing due to the warnings I posted!!! Have a look at 1gw's ramps. SLN down 70% over last few days. Byot, earlier this year, down 99.9% Rthm down 80%, trmr down 80%..GBO bust, STU bust. Do you not think it odd that someone who portrays himself as a well researched poster has virtually all his shares crash? |
Posted at 20/11/2024 17:56 by malcolmz1 The problem is HVO share price is about to test 18p. |
Posted at 20/11/2024 12:06 by sikhthetech Yump"The risks of no contract news and institutions stopping buying was talked about before your time back in July/August." Wrong. The red flag was when CF dumped majority of his holding in Feb, whilst the company was being talked up. Together with the huge >7m options awarded to the CEO, these were huge red flags. My assertions and warnings have been consistent and foresight. My assertions/opinions have been: These are being talked up so they can sell. The chairman DID sell majority of his holding in Feb 2024, whilst the company was being talked up. I said that's a red flag. Rampers ridiculed me by saying he still retains a sizeable holding!!! The chairman then dumped his entire holding in July 2024, just 4 working days after the TU. I said that was a huge red flag. The Chairman sells 28p/29p has set a ceiling to the share price I believe the chairman knows more about the company than any PI or II. The CEO has huge >7m options, which were back dated a year and start to exercise from Feb 2025. The shares will continue to be talked up. As far as I'm aware, Feb 2025 is still 3 months away!! Do you disagree? Awarding such huge options to 1 exec is a red flag. Cash. I believe clients largely paid for the new facility because HVO need to save cash for H2. Likewise the reasons why they don't pay normal dividends. Buying stops. The share price will drop when the II stops buying, as selling will continue. If there's huge demand then there's nothing stopping others entering the market. £200m mcap for a company with revenues of only £50m-£60m is too high. Questionable business model. Lack of 2025 revenue guidance is a red flag. These are being pumped/dumped by the same blnx gang, using multiple ids. |
Posted at 19/11/2024 14:01 by yump Taking profits is nothing to do with it - you need to know when in advance. Second-guessing my actions is irrelevant - its just avoiding the issue with your chart “method”This share price has been going down, which shows charts work. Welcome to the world of snake oil “science” I’m still waiting for you to point me in the direction of proof, but I don’t think you actually understand the difference between random coincidence and a validated system. Make 10 predictions of share price and timing, based on a specific chart movement and I might believe you personally have an uncanny predictive knack. That might be a start. But nobody ever rises to that challenge. PS you need to specify all those variables, otherwise you can just make any old claim at any old time. But then that’s your method isn’t it? Oh I forgot, you’re a super dooper trader. |
Posted at 07/10/2024 10:31 by sikhthetech Pierre,You don't find the chairman dumped his entire holding, whilst the company was being talked up as a huge red flag??? Really, feel free to state why? 3 months since he sold. Now end of Q3, week 1 of Q4 gone, still no news on those £40m contracts... "Please find something new and of interest to post. "tly is down 90% " Strange, how you never find anything new, isn't it? TLY announced £6m contracts recently and haven't announced any HVO. The chairman, CFO at TLY have been buying. What about the chairman of HVO, he's dumped his entire holding 3 months ago. c40% of IIs hold TLY. What about the 99.9% fall in share price of 1gw's share, Byot. Or his 80% fall in rthm/trmr or recent Inse share price fall etc... Funny how you never mention them and defend him. 1gw a good mate of yours??? How many multiple ids do you think 1gw and his mates use? ;-) |
Posted at 10/9/2024 10:09 by rivaldo Good, solid H1 results - and 100% visibility over revenues for this year already.Cavendish have reiterated their 42p target price and summarise as follows: "On track to meet all targets. Once again HVO has delivered on its targets, and with CW open we are increasingly confident that targets for both near- and longer-term are achievable, which will drive compound double-digit revenue and profit growth. — HVO is strongly positioned for future growth. The company has visibility on 100% of FY 2024 revenues and, and good visibility into FY 2025. We believe EBITDA margins will be broadly flat for the next year as the company invests for future growth, revenues are expected to continue their healthy growth trajectory. As a double-digit compounder we believe that the current FY2025E EV/sales and EV/EBITDA multiples of 2.4x and 9.9x respectively are too low, and reiterate our 42p price target, which is solidly underpinned by a 10-year DCF." The most interesting part of today's note was this: "In our view this robust revenue growth will continue as HVO benefits from: — An expanding pathogen portfolio, with ten new challenge agents manufactured over the past three years. With the move to CW and the availability of an in-house BSL-3 lab and secure quarantine facilities under one roof the ability to further expand the challenge agent portfolio will increase, as shown in figure 3 below. — The global biopharma community is becoming increasingly aware of the benefit of HCTs over conventional clinical studies from the perspective of time to delivery of results, reduction in clinical trial size and cost. — Greater capacity at CW in one location compared to the previous facilities. CW offers fifty beds in one location vs forty-three beds over four locations previously, spread between QMB and three floors at the Whitechapel facility. We understand that there is the ability to further utilise the space at CW to add additional quarantine rooms if required, and that the company has the option to lease additional space on an adjacent floor, ensuring that CW is fit for purpose for a number of years. — Revenue diversification. Although HVO is first and foremost a leading HCT firm, the recent major contract win to run a 1,000 volunteer field study (the only one in the UK) as part of a multinational phase 2b influenza drug field study indicates how management is looking to leverage its expertise in associated verticals while using existing infrastructure and capabilities. In addition to field studies, clinical trial design consulting via Venn, specialist standalone lab services, standalone patient and volunteer recruitment services (leveraging the FluCamp platform) and clinical site services all offer potential revenue streams in addition to HCTs which will help to drive efficiencies by improving staff utilisation. — Being able to leverage the somewhat unique FluCamp platform to rapidly recruit appropriate volunteers when necessary. Post the Covid pandemic governments, regulatory agencies and the global biopharma industry is more aware of the threat of another global pandemic, which many experts see as “when and not if”. As seen with Covid, HVO’s leading HCT capabilities can be invaluable in shortening the time to produce an effective vaccine and/or treatment when time is of the essence. — An ongoing ability to pass on sensible price rises to customers." |
Posted at 14/8/2024 13:01 by pierre oreilly stt, If you put as much effort into researching companies as you do to trying to deramp them, then you may end up with 5 baggers like hvo for me instead of 95% losers which is your experience, and source of your silly bitterness. Get rid of emotion mate. Oopse, too late, you've lost all your money already!.How many more times are you going to post EXACTLY the same post? Directors sometimes sell shares - that's why they run companies. The return from share sales from entrepreneurs who build successful companies far exceeds their salary. It's the reward they deserve. They aren't ltbh - they have a small company skillset and interest. They sell and move onto the next one - just as cf did with small companies before hvo. It was a matched sell with Octopus who bought them, and more since. You'd be better asking yourself what Octopus saw in hvo. Do you know of Greg at Octopus? He's pretty smart imv. Within a year, I expect Octopus will bid for all hvo shares, and who can blame them. CF couldnt have sold without trashing the price and Octopus simply couldn't have bought as many without driving the price much higher, so the matched trade satisfied both parties. You have to grab opportunities while they are there. Anyhow, hvo is no longer a penny punter pi share - the price is now governed by institutions operating at this market cap level and other big investors - hence why you constant boring repetitive post has no effect on the price. Can't you see that? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
